This was a planned secondary analysis of PROMISE/1077 study data to assess the impact of preterm and very preterm, antenatal ARVs, and infant feeding type on 24-month overall and HIV-free survival outcomes.  Maternal regimens included three arms: (a) oral zidovudine (ZDV) during pregnancy followed by a single dose of nevirapine (NVP) and double dose of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) at labor onset, followed by a one-week TDF/FTC “tail”; (b) antepartum zidovudine/lamivudine/boosted lopinavir continued through the first week post-delivery; and (c) antepartum TDF/FTC/boosted lopinavir through the first week post-delivery.  All infants received NVP prophylaxis for six weeks; qualifying breastfeeding dyads underwent further randomization to either continued daily infant NVP or maternal TDF-based ART through breastfeeding cessation.  3535 infants born to mothers enrolled between 2011 and 2015 were included in analyses.  Median GA at delivery was 39 weeks; 83% were born full-term and 17% preterm (14% born ≥34 to <37 weeks and 3% born <34 weeks).  Preterm birth <37 weeks was associated with decreased 24-month HIV-free survival compared to full-term birth.  Infants with antenatal TDF-based ART exposure had greater risk of HIV infection or death by 24 months compared to ZDV-based ART, when adjusted for breastfeeding.  Breastfeeding was protective against risk of HIV infection or death when adjusted for maternal antenatal ART arm.